Stacking up the various modalities – what do we find?
It’s time to talk about an particular target in AML because there are now a variety of different modalities involved since we last covered it, which makes it rather more intriguing than most. There’s antibodies, ADCs, CAR-T cell therapies, stem cells, and various bispecifics to name a few such examples.
To be clear, we’re not talking about CD123 here either, but rather an entirely different protein that is receiving increasing attention from multiple companies.
How does the evidence stack up? Will one particular approach stand out from all the others?
Next, perhaps what makes this post even more interesting is we have an engaging interview with one of the company CEO’s in this niche to share, so we can see how they view things from the lens of looking at things in a different way from many of the other competitors.
To learn more from our oncology coverage and get a heads up on our latest biotech expert interview, subscribers can log-in or you can click to gain access to BSB Premium Content.
Yesterday sudden and unexpected news from Seattle Genetics caused quite a stir…
“Seattle Genetics Announces Clinical Hold on Several Phase 1 Trials of Vadastuximab Talirine (SGN-CD33A).”
Part of the Seattle Genetics exhibit booth at #ASH16, taken with permission
In short, over 300 patients have been treated with the ADC and six experienced hepatotoxicity, including several cases of veno-occlusive disease, with four fatalities.
We’ve written about AML several times recently and also received a number of reader questions on this latest development, so it’s time to explore the issue in more depth and look at the implications. We also include some expert commentary from a leukemia specialist for their take on the issue.
To learn more about our insights, Subscribers can log in.
Some cancer conferences attract more questions and queries than others.
Old Town San Diego
Interestingly, ASH is always a popular meeting for attendees and readers alike, so it is good to see another batch of critical questions come in so soon after the last one. It’s a while since we did two BSB reader Q&A mailbags from a single meeting!
Not surprisingly, there were also a bunch of questions on CAR T cell therapies, which continue to dominate readers minds, as well as related issues. Here, we answer the most pressing questions that have come in over the last week.
Subscribers can log-in below